Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 23Neoplasms 19Cancer Pain 9Colonic Neoplasms 7Breakthrough Pain 7Agnosia 7Breast Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Chronic Pain 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Pain, Postoperative 3Sarcoma 2Pleural Effusion, Malignant 2Lymphoma, Follicular 2Diverticulosis, Colonic 2Carcinoma, Hepatocellular 2Burns 2Brain Neoplasms 2Anemia, Sickle Cell 2post laminectomy syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1

Interventions

Denosumab 2radium Ra 223 dichloride 1Radiotherapy 1Radiation 1QL1206 1Magnetic Resonance Spectroscopy 1Hydroxychloroquine 1Fentanyl 1Exercise 1Docetaxel 1Continuous Glucose Monitoring 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bone Metastases × Fentanyl × Clear all
NCT03071744 2019-12-09

Lazanda in Cancer Patients Receiving Palliative Radiation

University of California, San Diego

Phase 2 Terminated
6 enrolled 10 charts

Bone Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡